Bill Gates, the founder of Microsoft and world-renowned philanthropist, announced plans to launch a comprehensive micronutrient supplement designed specifically for pregnant women in Indonesia through the Gates Foundation. The initiative aims to address anemia, a common health condition affecting many women.
Gates revealed this plan during a visit to the Presidential Palace in Jakarta, where he met with Indonesian President Prabowo Subianto. The meeting also marked the 25th anniversary of the Gates Foundation.
At the Istana Merdeka, Gates stated: “We’re calling this a prenatal multi-micronutrient supplement, which can replace the currently widely-used folic acid and amino acid supplements.”
He pointed out that this product, known as “MMS,” contains multiple vitamins and trace elements essential for fetal development.
Gates disclosed that since Indonesia is still facing challenges related to malnutrition, the country will be one of the first to introduce this supplement.
He emphasized that many women are facing challenges with anemia and insufficient amino acid intake, and this supplement is one of the solutions proposed by the Gates Foundation.
He said: “Our foundation hopes to alleviate anemia through this supplement. Therefore, we plan to launch it in Indonesia in one to two years.”
According to information from the Gates Foundation on social media, this MMS supplement has been proven safe and effective in preventing malnutrition in pregnant women and infants.
Each MMS tablet contains 15 crucial vitamins and minerals for pregnancy, priced at $2.60, approximately 43,000 Indonesian Rupiah (based on the exchange rate on Wednesday).
Besides promoting the prenatal micronutrient supplement, another focus of Gates’ visit to Indonesia was to discuss global health, nutrition, financial inclusion, and public digital infrastructure with President Prabowo.
After the meeting, Prabowo pointed out that one of the key topics discussed with Gates was the ongoing clinical trials of the tuberculosis (TB) vaccine in Indonesia.
Currently, the Gates Foundation is funding research and trials for the TB vaccine in multiple countries. Indonesia is one of the participating countries and has entered the clinical trial phase.
Gates revealed this plan during a visit to the Presidential Palace in Jakarta, where he met with Indonesian President Prabowo Subianto. The meeting also marked the 25th anniversary of the Gates Foundation.
At the Istana Merdeka, Gates stated: “We’re calling this a prenatal multi-micronutrient supplement, which can replace the currently widely-used folic acid and amino acid supplements.”
He pointed out that this product, known as “MMS,” contains multiple vitamins and trace elements essential for fetal development.
Gates disclosed that since Indonesia is still facing challenges related to malnutrition, the country will be one of the first to introduce this supplement.
He emphasized that many women are facing challenges with anemia and insufficient amino acid intake, and this supplement is one of the solutions proposed by the Gates Foundation.
He said: “Our foundation hopes to alleviate anemia through this supplement. Therefore, we plan to launch it in Indonesia in one to two years.”
According to information from the Gates Foundation on social media, this MMS supplement has been proven safe and effective in preventing malnutrition in pregnant women and infants.
Each MMS tablet contains 15 crucial vitamins and minerals for pregnancy, priced at $2.60, approximately 43,000 Indonesian Rupiah (based on the exchange rate on Wednesday).
Besides promoting the prenatal micronutrient supplement, another focus of Gates’ visit to Indonesia was to discuss global health, nutrition, financial inclusion, and public digital infrastructure with President Prabowo.
After the meeting, Prabowo pointed out that one of the key topics discussed with Gates was the ongoing clinical trials of the tuberculosis (TB) vaccine in Indonesia.
Currently, the Gates Foundation is funding research and trials for the TB vaccine in multiple countries. Indonesia is one of the participating countries and has entered the clinical trial phase.